Waksal promises big things for his new drug firm

With his five-year prison stint for insider trading receding in the background, Sam Waksal (photo) is back in visionary mode, telling New York Times writer Andrew Pollack that his new biotech company will be bigger and better than ImClone ever was. Report

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.